Sarah K. Wise, Cecelia Damask, Lauren T. Roland, Charles S. Ebert et al.
BACKGROUND: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR-Allergic Rhinitis 2023 update presents 144 individual topics ...
Jean Bousquet, Holger J. Schünemann, João Fonseca, Bolesław Samoliński et al.
Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient e...
Jean Bousquet, Peter W. Hellings, Ioana Agache, Anna Bedbrook et al.
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidel...
Jean Bousquet, Peter W. Hellings, Ioana Agache, Flore Amat et al.
Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of provi...
Anne K. Ellis, James H. Day
Anaphylaxis is a severe systemic allergic reaction that is potentially fatal. It requires prompt recognition and immediate management. Anaphylaxis has a rapid onset with multiple organ-system involvement and is mostly caused by specific antigens in sensitized individuals. Reactions typically follow ...
Sean P. Allen, Shabeena Khan, Shui‐Pang Tam, Marlys L. Koschinsky et al.
Lp(a) is a major inherited risk factor for premature atherosclerosis. The mechanism of Lp(a) atherogenicity has not been elucidated, but likely involves both its ability to interfere with plasminogen activation and its atherogenic potential as a lipoprotein particle after receptor-mediated uptake. W...
Eli O. Meltzer, Paul H. Ratner, Claus Bachert, Warner Carr et al.
BACKGROUND: It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response using novel efficacy analyses (including a responder analysis), and (2) to compare the effica...
James H. Day, Maureen P. Briscoe, Michael D. Widlitz
Background Allergic rhinitis affects nearly one in 10 Americans. Cetirizine is a newer once-daily selective H1-antagonist. In traditional clinical trials, cetirizine has been shown to be safe and effective for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria...
Jean Bousquet, Erik Melén, Tari Haahtela, Gerard H. Koppelman et al.
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease," coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, i...
Eli O. Meltzer, Craig LaForce, Paul H. Ratner, David Price et al.
Many patients with allergic rhinitis (AR) have uncontrolled symptoms despite available treatment options. This study was designed to evaluate the efficacy and safety of MP29-02 (a novel intranasal formulation of fluticasone propionate [FP] and azelastine [AZ] hydrochloride), compared with monotherap...
David Price, Shailen Shah, Sanjay Bhatia, Claus Bachert et al.
BACKGROUND AND OBJECTIVE: MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is significantly better than first-line therapy for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR), and is well tolerated following 52 ...
Rupinder Kaur, Varinder Singh, Pratima Kumari, Ravinder J. Singh et al.
Cell adhesion molecules (CAM) including the intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) are from the immunoglobulin family which regulates leukocyte adherence to endothelial muscles in acute or chronic inflammatory states [1]. TNF-α, a proinflammatory cy...
Chenbo Ding, Wendong Tang, Xiaobo Fan, Xiyong Wang et al.
Pseudopodium-enriched atypical kinase 1 (PEAK1), a novel non-receptor tyrosine kinase, has been demonstrated to act as an oncogenic regulator in breast and pancreatic cancers. However, the role of PEAK1 in the progression and metastasis of lung cancer is still unknown. Here, we observed that ectopic...
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao et al.
PURPOSE: Adjuvant chemotherapy is one of the significant treatments for colon cancer in clinic. However, it does not achieve the desired therapeutic efficacy, largely due to chemotherapeutic resistance. Integrinβ6 (ITGB6) is expressed in malignant colonic epithelia, but not in normal epithelia, and ...
Justyna Pawłowska, Anna Mikosik, M Soroczynska-Cybula, Agnieszka Jóźwik et al.
Rheumatoid arthritis (RA) and osteoarthritis (OA) are chronic diseases associated with morphological joint changes. Synovial membrane (SM) involvement was established for RA, but the data for OA are limited, because OA is usually regarded as noninflammatory disease. Changes in immune system in RA ar...